ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
다우존스 지수
38,686.32
1.51%
Bitcoin
67,655.75
0.26%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) 뉴스

RNAZ

TransCode Therapeutics (RNAZ)

TransCode Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:RNAZ
일자시간출처헤드라인심볼기업
2024/05/2922:15GlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
2024/05/2105:00Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
2024/05/1606:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
2024/05/1406:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
2024/05/1321:30GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
2024/05/1105:50Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
2024/05/1105:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
2024/04/1522:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
2024/04/0322:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
2024/03/2821:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
2024/03/1122:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
2024/03/0706:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
2024/02/2022:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
2024/02/1606:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
2024/02/1410:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
2024/02/0106:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
2024/02/0106:05GlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/2922:30GlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/2306:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/2306:45GlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/2011:57Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1903:27GlobeNewswire Inc.TransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1900:39Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1721:06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1706:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1306:05GlobeNewswire Inc.TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEONASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1122:22Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
2024/01/1122:00GlobeNewswire Inc.TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
2024/01/0906:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
 검색 관련기사 보기:NASDAQ:RNAZ

최근 히스토리

NASDAQ
AMZN
Amazon.com
FX
USDEUR
US Dollar vs Euro
AMEX
XLE
Energy Select Sector SPDR
NYSE
AXP
American Express
PM
XAUUSD
Gold vs US Dollar
NASDAQ
NVDA
NVIDIA
NYSE
CVX
Chevron
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
USOTC
ADDYY
Adidas (QX)
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유